About Oncoinvent

Oncoinvent ASA was founded in 2010 by Dr. Roy H. Larsen, Professor of Clinical Oncology Øyvind Bruland, Dr. Tina Bønsdorff, and Dr. Thora Jonasdottir. Oncoinvent’s technology basis uses highly potent alpha radiation from radionuclides that are delivered to kill cancer cells. Larsen and Bruland are serial-entrepreneurs in the radiopharma space and the inventors behind Xofigo®, the first and so far only alpha radiation based cancer drug to be approved by the FDA and EMA. In the early days, the founders committed to designing better cancer treatments by applying known physical and chemical principles in new ways to maximize medical benefits while minimizing potential safety concerns. This approach has allowed Oncoinvent to explore and develop multiple technologies before selecting the company’s lead product candidate, Radspherin®.

Oncoinvent has established its own manufacturing facility in Oslo together with a highly skilled and capable organization with significant experience in the development of radiopharmaceuticals. The internal manufacturing and supply chain capabilities have the capacity to manufacture and supply Radspherin® for multi-center Phase 2 clinical studies in Europe and North America. This in-house approach has resulted in a unique team with a highly integrated operation.

Oncoinvent is listed on the Euronext Growth Oslo (ONCIN:OL).